Vutrisiran: A Game-Changer in TTR Amyloidosis Therapy

TTR amyloidosis is a slowly progressive multisystem disorder caused by misfolding and extracellular deposition of the transthyretin protein as amyloid fibrils in the various tissues of the body. The disease manifests itself in two major subtypes: Hereditary Transthyretin- Mediated Amyloidosis (hATTR) and wild-type transthyretin amyloidosis (ATTRwt) [1-3]. TTR is a transport protein primarily synthesized by the liver. It is responsible for the transportation of thyroxine (T4) and Retinol-Binding Protein (RBP), bound to vitamin A [4,5]. Under normal physiological conditions, TTR exists as a tetramer that maintains structural stability. However, mutations in the TTR gene (as seen in hATTR) or age-related destabilization of the wildtype protein (as seen in ATTRwt) can result in tetramer dissociation, leading to monomer misfolding and subsequent aggregation into amyloid fibrils [1,6].

The deposition of amyloid fibrils in several organ systems results in a wide spectrum of clinical manifestations. In hATTR, the most common phenotypic presentations involve polyneuropathy, cardiomyopathy, and autonomic neuropathy [7]. Neuropathy due to hATTR is typified by progressive sensorimotor deficits and considerable disability [8,9]. Cardiomyopathy in TTR amyloidosis manifests as either restrictive cardiomyopathy with heart failure or arrhythmic abnormalities within the course of the disease. The wild type (ATTRwt) form, formerly termed senile systemic amyloidosis, affects the heart with a consequent major cause of Heart Failure with Preserved Ejection Fraction (HFpEF) in elderly patients [10,11]. Other organs that may be involved, including the GI tract, kidneys, and eyes, complicate disease management further.

For a long time, TTR amyloidosis was considered a rare and fatal condition with limited treatment options mostly confined to supportive care and organ transplantation in severe cases. However, better knowledge of the disease has led to the development of novel targeted therapies for stabilizing TTR, reducing its production, or inducing amyloid clearance [12]. Among these, vutrisiran, an RNA interference (RNAi) therapeutic, appears to be one of the most promising treatment options for patients with hATTR [13,14]. This review provides an in-depth analysis of vutrisiran, including its mechanism of action, clinical efficacy, safety profile, and its role in the evolving treatment landscape of TTR amyloidosis.

Vutrisiran is a double-stranded Small Interfering Ribonucleic Acid (siRNA) therapeutic specifically designed to target and silence the TTR gene in hepatocytes, thus reducing the production of both mutant and wild-type transthyretin proteins. The mechanism of action of vutrisiran is fundamentally based on RNA Interference (RNAi) pathways, which form a natural cellular process that restricts gene expression by degrading target mRNA [14,15]. Vutrisiran operates via the asialoglycoprotein receptor for the uptake by hepatocytes upon subcutaneous administration, in which it is conjugated to N-acetylgalactosamine (GalNAc). Once taken inside the liver cell, vutrisiran is incorporated into the RNA-Induced Silencing-Complex Complex (RISC). This complex selectively binds to the complementary TTR mRNA sequence, leading to the cleavage of the mRNA and ultimately to its degradation. This leads to a marked reduction in the production of the transthyretin protein and a reduction in circulating levels of both mutant and wild-type TTR [16,17].

By reducing hepatic TTR synthesis, vutrisiran prevents the formation and accumulation of amyloid fibrils in tissues, thereby slowing disease progression. Infrequent dosing, broadly every three months, allows for a prolonged pharmacodynamic effect promotion of patient compliance and comfort, as contrasted with other RNAi therapies [18,19,20].

The efficacy of vutrisiran has been evaluated in several clinical trials:
A. HELIOS-A Study: This pivotal phase 3, open-label, multinational study performed by Adams et al. assessed the efficacy and safety of vutrisiran in patients with hATTR amyloidosis with polyneuropathy. Patients aged 18-85 years with a documented TTR variant and neurological impairment scores were included. Compared to an external placebo group, patients given vutrisiran showed statistically significant differences in changes in neuropathy impairment scores and quality of life outcomes. The drug was generally well-tolerated, with most adverse events being mild or moderate in severity [21,22].
B. HELIOS-B Study: This randomized, double-blind, placebocontrolled phase 3 trial led by Fontana et al. evaluated vutrisiran in patients with ATTR-CM. The trial showed a 28% relative reduction in the composite endpoint of all-cause mortality and recurrent cardiovascular events for vutrisiran as compared to placebo. Moreover, clinically significant improvements on functional capacity and quality of life metrics were observed [15,23,24,25].

In June 2022, the U.S. Food and Drug Administration (FDA) approved vutrisiran, marketed as AMVUTTRA®, for the treatment of the polyneuropathy of hATTR amyloidosis in adults. This approval was based on the positive outcomes from the HELIOS-A study [26]. Furthermore, in November 2024, the FDA accepted a Supplemental New Drug Application (sNDA) for vutrisiran for the treatment of ATTR amyloidosis with cardiomyopathy, with a Prescription Drug User Fee Act (PDUFA) target date set for March 23, 2025 [27].

Within HELIOS-A and HELIOS-B clinical trials, the safety profile of vutrisiran has been extensively studied. Overall, vutrisiran was shown to be well tolerated, with most adverse events being mild to moderate in severity [28]. Commonly cited side effects include injection site reactions (redness, swelling, and mild discomfort); these reactions are typically transient and self-resolving without the need for further medical intervention. Other commonly observed adverse effects include transient increases in liver enzyme levels (alanine aminotransferase and aspartate aminotransferase), although these elevations were asymptomatic and rarely required discontinuation of treatment [28,29]. One of the key advantages of vutrisiran is its favorable safety profile compared to other RNAibased therapies. In contrast to older-generation siRNA therapeutics, systemic immune response is less likely with vutrisiran largely owing to its chemical stability and hepatocyte-specific targeting by GalNAc conjugation. Additionally, its infrequent dosing schedule minimizes the likelihood of cumulative toxicity [17,28,30].

In clinical trials, there were no significant differences in major cardiovascular adverse events between vutrisiran-treated patients and placebo-treated subjects. Moreover, there were also no reports of drug-induced neuropathy-a prior concern with certain TTRstabilizing therapies [31]. Long-term safety data collection for vutrisiran, particularly in relation to the compound’s effect on renal function and other organ systems, is still ongoing. Additional postmarketing surveillance and real-world evidence studies will further illuminate the safety profile of vutrisiran for elderly patients and those with advanced cardiac involvement.

With the advent of disease-modifying medications, such as TTR stabilizers (tafamidis), gene-silencing agents (patisiran, vutrisiran), and amylin-fibril disruptors, the landscape of TTR amyloidosis treatment has evolved significantly. Among them, vutrisiran stands out for its ease of administration, durability of action, and safety profile [32]. While tafamidis acts as a TTR stabilizer, binding to the thyroxine-binding sites on the TTR tetramer, vutrisiran directly suppresses TTR protein synthesis. Although tafamidis has been shown to be effective in delaying disease progression, it does not decrease existing amyloid deposits. RNAi therapies like vutrisiran and patisiran allow for more comprehensive treatment as they have dual actions of both lowering TTR and helping prevent additional formation of fibrils [32,33]. Patisiran, another siRNA therapy, is administered through intravenous infusion once every three weeks, whereas vutrisiran is given subcutaneously once every three months, making it a potentially more convenient option for patients. Moving towards less frequent dosing schedules is truly a big step in enhancing treatment convenience and adherence [30,34]. Future directions for vutrisiran and similar RNAi therapies are combination strategies with upcoming amyloid-clearance agents for enhanced therapeutic outcomes. The ongoing clinical trials are also looking at the efficacy of vutrisiran in ATTRwt, which remains an area of unmet need. Further research into long-term outcomes and head-on comparisons with existing therapies could provide valuable insights toward optimizing treatment paradigms for TTR amyloidosis.

Vutrisiran represents a great advancement in the treatment of TTR amyloidosis by RNA interference to strong prevention of TTR production and progression of the disease. With its ease of administration and favorable side effects profile, it should be a compelling option for patients with hATTR. Vutrisiran does strike a balance between efficacy, safety, and ease of use compared to other available therapies. As the treatment landscape for TTR amyloidosis continues to evolve, further research will be crucial in optimizing its use and exploring potential combination therapies. Long-term real-world data will provide additional insights into its effectiveness and safety in diverse patient populations. Ultimately, the integration of vutrisiran into clinical practice represents a promising step forward in improving outcomes for patients with TTR amyloidosis.

1. Ruberg FL, Berk JL (2012) Transthyretin (TTR) cardiac amyloidosis. Circulation 126(10): 1286-1300.
2. Sekijima Y (2015) Transthyretin (ATTR) amyloidosis: Clinical spectrum, molecular pathogenesis and disease-modifying treatments. Journal of Neurology, Neurosurgery & Psychiatry 86(9): 1036-1043.
3. Hund E, Linke RP, Willig F, Grau A (2001) Transthyretin-associated neuropathic amyloidosis: Pathogenesis and treatment. Neurology 56(4): 431-435.
4. Vieira M, Saraiva MJ (2014) Transthyretin: A multifaceted protein. Biomolecular Concepts 5(1): 45-54.
5. Weiss JM, Andersson PL, Lamoree MH, Leonards PE, van Leeuwen SP, et al. (2009) Competitive binding of poly-and perfluorinated compounds to the thyroid hormone transport protein transthyretin. Toxicological Sciences 109(2): 206-216.
6. Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE (2003) Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 10(3): 160-184.
7. Gertz MA (2017) Hereditary ATTR amyloidosis: Burden of illness and diagnostic challenges. Am J Manag Care 23(7 Suppl): S107-112.
8. Luigetti M, Romano A, Di Paolantonio A, Bisogni G, Sabatelli M (2020) Diagnosis and treatment of hereditary transthyretin amyloidosis (hATTR) polyneuropathy: Current perspectives on improving patient care. Therapeutics and Clinical Risk Management 16: 109-123.
9. Kaku M, Berk JL (2019) Neuropathy associated with systemic amyloidosis. Seminars in Neurology 39(5): 578-588.
10. Dungu JN, Anderson LJ, Whelan CJ, Hawkins PN (2012) Cardiac transthyretin amyloidosis. Heart 98(21): 1546-1554.
11. Porcari A, Fontana M, Gillmore JD (2022) Transthyretin cardiac amyloidosis. Cardiovascular Research 118(18): 3517-3535.
12. Adams D, Koike H, Slama M, Coelho T (2019) Hereditary transthyretin amyloidosis: A model of medical progress for a fatal disease. Nature Reviews Neurology 15(7): 387-404.
13. Patterson J (2023) Small interfering RNA (siRNA)-based therapeutics. Drug and Therapeutics Bulletin 61(5): 72-76.
14. Dzau VJ, Hodgkinson CP (2024) RNA therapeutics for the cardiovascular system. Circulation 149(9): 707-716.
15. Fontana M, Berk JL, Gillmore JD, Witteles RM, Grogan M, et al. (2024) Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. New England Journal of Medicine 392(1): 33-44.
16. Sten S, Cardilin T, Antonsson M, Gennemark P (2023) Plasma pharmacokinetics of n-acetylgalactosamine-conjugated small-interfering ribonucleic acids (GalNAc-Conjugated siRNAs). Clinical Pharmacokinetics 62(12):1661-1672.
17. Habtemariam BA, Karsten V, Attarwala H, Goel V, Melch M, et al. (2021) Single‐dose pharmacokinetics and pharmacodynamics of transthyretin targeting n‐acetylgalactosamine–small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects. Clinical Pharmacology & Therapeutics 109(2): 372-382.
18. Keller DM, Straburzyńska-Migaj E, Lesiak M (2025) Advancing treatments for transthyretin amyloid cardiomyopathy: Innovations in RNA silencing, gene editing, TTR stabilization, and degradation. Polish Heart Journal (Kardiologia Polska) 83(2): 121-137.
19. Aimo A, Castiglione V, Rapezzi C, Franzini M, Panichella G (2022) RNA-targeting and gene editing therapies for transthyretin amyloidosis. Nature Reviews Cardiology 19(10): 655-667.
20. Ioannou A, Fontana M, Gillmore JD (2023) RNA targeting and gene editing strategies for transthyretin amyloidosis. BioDrugs 37(2): 127-142.
21. Adams D, Tournev IL, Taylor MS, Coelho T, Planté-Bordeneuve V, et al. (2023) Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: A randomized clinical trial. Amyloid 30(1): 1-9.
22. Adams D, Tournev IL, Taylor MS, Coelho T, Planté-Bordeneuve V, et al. (2021) HELIOS-A: 9-month results from the phase 3 study of vutrisiran in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy (1234). Neurology 96(15_supplement): 1234.
23. Maurer SM, Berk LJ, Damy T, Sheikh F, González-Costello J, et al. (2025) Exploratory analyses from HELIOS-B, a phase 3 study of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. Archives of Cardiovascular Diseases 118(1): S28.
24. Collins C, Cios TJ, Walker J (2025) RNA Interference in Amyloid: What's new from HELIOS-B? Journal Of Cardiothoracic and Vascular Anesthesia 39(3): 565-568.
25. Pedicino D, Volpe M (2025) Weekly journal scan: HELIOS-B sheds light on new therapeutic options for transthyretin amyloidosis with cardiomyopathy. Eur Heart J 46(11): 1080-1081.
26. Senior M (2023) Fresh from the biotech pipeline: Fewer approvals, but biologics gain share. Nature Biotechnology 41(2):174-182.
27. Hellenbart EL, Ipema HJ, Rodriguez‐Ziccardi MC, Krishna H, DiDomenico RJ (2024) Disease‐modifying therapies for amyloid transthyretin cardiomyopathy: Current and emerging medications. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 45(2): 124-144.
28. Liu Y, Li H, Hu C, Tan L, Yin P, et al. (2024) A real-world pharmacovigilance analysis for transthyretin inhibitors: Findings from the FDA adverse event reporting database. Frontiers in Pharmacology 15: 1368244.
29. Keam SJ (2022) Vutrisiran: First approval. Drugs 82(13): 1419-1425.
30. Karimi MA, Esmaeilpour Moallem F, Gholami Chahkand MS, Azarm E, Emami Kazemabad MJ, et al. (2024) Assessing the effectiveness and safety of patisiran and vutrisiran in ATTRv amyloidosis with polyneuropathy: A systematic review. Frontiers in Neurology 15: 1465747.
31. Merlini G (2025) Vutrisiran for ATTR amyloidosis with cardiomyopathy. New England Journal of Medicine 392(1): 83-84.
32. Maurer MS, Soman P, Hernandez A, Garcia-Pavia P, Signorovitch J, et al. (2024) Advancing transthyretin amyloidosis drug development in an evolving treatment landscape: Amyloidosis forum meeting proceedings. Advances in Therapy 41(7): 2723-2742.
33. Merkel M, Danese D, Chen C, Wang J, Wu A, et al. (2023) Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy. Expert Opinion on Pharmacotherapy 24(10): 1205-1214.
34. Polydefkis M, Birklein F, Sekijima Y, Pareyson D, Cruz MW, et al. (2023) Comparison of efficacy outcomes with vutrisiran vs. Patisiran in hATTR amyloidosis with polyneuropathy: Post-hoc analysis of the HELIOS-A study (S14. 003). Neurology 100(17_supplement_2): 2963.